National Vision Competitors

Elanco Animal Health (NYSE:ELAN) and National Vision (NASDAQ:EYE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Volatility & Risk

Elanco Animal Health has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, National Vision has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.

Profitability

This table compares Elanco Animal Health and National Vision's net margins, return on equity and return on assets.

Institutional & Insider Ownership

86.8% of Elanco Animal Health shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by insiders. Comparatively, 2.6% of National Vision shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Elanco Animal Health and National Vision's gross revenue, earnings per share and valuation.

Elanco Animal Health has higher revenue and earnings than National Vision. Elanco Animal Health is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Elanco Animal Health and National Vision, as provided by MarketBeat.com.

Elanco Animal Health presently has a consensus target price of $30.50, indicating a potential downside of 5.69%. National Vision has a consensus target price of $43.25, indicating a potential downside of 9.52%. Given Elanco Animal Health's higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than National Vision.

National Vision (NASDAQ:EYE) and STERIS (NYSE:STE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares National Vision and STERIS's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares National Vision and STERIS's revenue, earnings per share and valuation.

STERIS has higher revenue and earnings than National Vision. STERIS is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

90.0% of STERIS shares are held by institutional investors. 2.6% of National Vision shares are held by insiders. Comparatively, 1.2% of STERIS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for National Vision and STERIS, as provided by MarketBeat.

National Vision presently has a consensus target price of $43.25, indicating a potential downside of 9.52%. STERIS has a consensus target price of $213.50, indicating a potential upside of 20.10%. Given STERIS's higher probable upside, analysts clearly believe STERIS is more favorable than National Vision.

Volatility & Risk

National Vision has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, STERIS has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500.

Summary

STERIS beats National Vision on 9 of the 14 factors compared between the two stocks.

National Vision (NASDAQ:EYE) and Abiomed (NASDAQ:ABMD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Profitability

This table compares National Vision and Abiomed's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares National Vision and Abiomed's revenue, earnings per share and valuation.

Abiomed has lower revenue, but higher earnings than National Vision. National Vision is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

National Vision has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Abiomed has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for National Vision and Abiomed, as provided by MarketBeat.

National Vision currently has a consensus target price of $43.25, indicating a potential downside of 9.52%. Abiomed has a consensus target price of $300.00, indicating a potential downside of 7.78%. Given Abiomed's higher probable upside, analysts plainly believe Abiomed is more favorable than National Vision.

Institutional & Insider Ownership

94.0% of Abiomed shares are owned by institutional investors. 2.6% of National Vision shares are owned by insiders. Comparatively, 3.4% of Abiomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Abiomed beats National Vision on 9 of the 14 factors compared between the two stocks.

National Vision (NASDAQ:EYE) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Profitability

This table compares National Vision and Bio-Techne's net margins, return on equity and return on assets.

Risk and Volatility

National Vision has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for National Vision and Bio-Techne, as provided by MarketBeat.

National Vision currently has a consensus target price of $43.25, indicating a potential downside of 9.52%. Bio-Techne has a consensus target price of $352.30, indicating a potential downside of 6.16%. Given Bio-Techne's higher probable upside, analysts plainly believe Bio-Techne is more favorable than National Vision.

Valuation and Earnings

This table compares National Vision and Bio-Techne's revenue, earnings per share and valuation.

Bio-Techne has lower revenue, but higher earnings than National Vision. National Vision is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

93.8% of Bio-Techne shares are owned by institutional investors. 2.6% of National Vision shares are owned by insiders. Comparatively, 3.8% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Bio-Techne beats National Vision on 9 of the 14 factors compared between the two stocks.

Charles River Laboratories International (NYSE:CRL) and National Vision (NASDAQ:EYE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Valuation & Earnings

This table compares Charles River Laboratories International and National Vision's top-line revenue, earnings per share (EPS) and valuation.

Charles River Laboratories International has higher revenue and earnings than National Vision. Charles River Laboratories International is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Charles River Laboratories International and National Vision's net margins, return on equity and return on assets.

Institutional & Insider Ownership

92.3% of Charles River Laboratories International shares are owned by institutional investors. 1.9% of Charles River Laboratories International shares are owned by company insiders. Comparatively, 2.6% of National Vision shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Charles River Laboratories International has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, National Vision has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Charles River Laboratories International and National Vision, as reported by MarketBeat.

Charles River Laboratories International currently has a consensus price target of $241.5625, indicating a potential downside of 15.97%. National Vision has a consensus price target of $43.25, indicating a potential downside of 9.52%. Given National Vision's stronger consensus rating and higher probable upside, analysts clearly believe National Vision is more favorable than Charles River Laboratories International.

Summary

Charles River Laboratories International beats National Vision on 9 of the 14 factors compared between the two stocks.

BioMarin Pharmaceutical (NASDAQ:BMRN) and National Vision (NASDAQ:EYE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Valuation and Earnings

This table compares BioMarin Pharmaceutical and National Vision's top-line revenue, earnings per share (EPS) and valuation.

National Vision has higher revenue and earnings than BioMarin Pharmaceutical. National Vision is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioMarin Pharmaceutical and National Vision's net margins, return on equity and return on assets.

Institutional and Insider Ownership

97.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 2.2% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 2.6% of National Vision shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

BioMarin Pharmaceutical has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, National Vision has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for BioMarin Pharmaceutical and National Vision, as reported by MarketBeat.com.

BioMarin Pharmaceutical presently has a consensus price target of $117.3636, indicating a potential upside of 50.64%. National Vision has a consensus price target of $43.25, indicating a potential downside of 9.52%. Given BioMarin Pharmaceutical's higher probable upside, research analysts clearly believe BioMarin Pharmaceutical is more favorable than National Vision.

Summary

National Vision beats BioMarin Pharmaceutical on 8 of the 14 factors compared between the two stocks.